---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-23-000063"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:40:07.682825+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Salarius explores strategic alternatives, cuts workforce >50% after Q2 net loss of $3.9M

## Summary
- FDA removed partial clinical hold on seclidemstat Phase 1/2 Ewing sarcoma trial.
- SP-3164 received FDA IND clearance for relapsed/refractory NHL Phase 1 trial.
- Cash $11.5M as of June 30, expected to fund operations through Q4 2023.
- Net loss Q2 2023 was $3.9M ($1.43/share) vs $4.7M ($2.20/share) in Q2 2022.
- Implementing cost-savings plan with >50% workforce reduction to extend resources.

## SEC filing metadata
- accession: 0001615219-23-000063
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521923000063/0001615219-23-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521923000063/flks-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-23-000063
- JSON: https://secwatch.observer/filing/0001615219-23-000063.json
- Plain text: https://secwatch.observer/filing/0001615219-23-000063.txt

## Key facts
- Earnings Releases
  Decoy Therapeutics Inc. reported three and six months ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $3.9 million, or $1.43 per share, EPS $1.43 per share.
  - Period: three and six months ended June 30, 2023
  - Net income: Net loss for the second quarter of 2023 was $3.9 million, or $1.43 per share
  - EPS: $1.43 per share
  - Result: reported results
  source text: reported financial results for the three and six months ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1615219/000161521923000063/0001615219-23-000063-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.